Company profile
CVRx, Inc.
NASDAQ: CVRX · Healthcare · Medical - Devices
#415 of 1,418 Healthcare companies by revenue56th-percentile growth
EA Score
50DFH 44DQ 52GM 64SS 51
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, filing timeliness · ↓ listing tenure, return on equity
Methodology →Revenue TTM
$59.1M
Rev growth YoY (TTM)
+11.7%
Net income (FY)
-$53.3M
Employees
223
as of 2026-08-14
Market cap
$78.0M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$56.7M$56.7M2025
Net income-$53.3M-$53.3M2025
Operating income-$51.3M-$51.3M2025
Total assets$104.8M$104.8M2025
Liabilities$65.5M$65.5M2025
Equity$39.3M$39.3M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is CVRx, Inc.’s revenue?
CVRx, Inc. booked $56.7M in FY2025 revenue, growing 10% year over year — about the middle of the pack among Healthcare companies we track, at a -94.1% net margin.
Peers · Healthcare
Etao International Co., Ltd.——Flower One Holdings Inc.——Champions Oncology, Inc.——HLS Therapeutics Inc.64C908 Devices Inc.60CNektar Therapeutics50DNeighbors
Hennepin →Key facts
CEOKevin Hykes
SectorHealthcare
IndustryMedical - Devices
HeadquartersMinneapolis, MN
ExchangeNASDAQ: CVRX
Employees223
IPO date2021-06-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.